Enhancing synapses to improve memory in Alzheimer's disease
Development of a small-molecule that enhances tripartite synapses for Alzheimers disease
This study is testing a new medication called M3 that could help improve memory by strengthening connections in the brain, and it aims to eventually help people with Alzheimer's disease feel better and think more clearly.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10474460 on NIH RePORTER |
What this research studies
This research focuses on developing a new small-molecule compound called M3 that aims to enhance the structure and function of synapses, which are crucial for memory. The study has shown promising results in mouse models of Alzheimer's disease, demonstrating improvements in cognitive functions and reductions in neurodegeneration. The research will progress through several phases, including preparation for clinical trials and testing different dosing strategies to ensure safety and effectiveness. Patients may eventually benefit from a new treatment that targets the underlying causes of memory loss in Alzheimer's.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those experiencing early symptoms of cognitive decline.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that significantly improves memory and cognitive function in Alzheimer's disease patients.
How similar studies have performed: Previous research has shown success with similar approaches in enhancing synaptic function, but this specific compound and its effects in humans are novel.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Lin, Chien-Liang Glenn — Ohio State University
- Study coordinator: Lin, Chien-Liang Glenn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.